Global Peripheral Blood Mononuclear Cells Research Report 2023: R&D Revolution - PBMCs Paving the Way for Medical Breakthroughs
DUBLIN, Oct. 4, 2023 /PRNewswire/ -- The "Peripheral Blood Mononuclear Cells Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product, By Application, By Techniques, By Source, By Region, Competition, Forecast and Opportunities" report has been added to ResearchAndMarkets.com's offering.
Global peripheral blood mononuclear cells market was valued at USD 235.68 million in 2022 and is anticipated to grow at a CAGR of 10.39% during the period 2023-2028 owing to the rising rate in the number of cell therapies, high demand of research, and development for toxicology testing and reaction mechanism of the compound responsible for new and stable development of products.
For instance, in June 2023, a study published in the National Library of Medicine assessed the immune response of peripheral blood mononuclear cells (PBMC) that were infected in vitro with the Colombian strain (Col) of Trypanosoma cruzi and treated with Benzonidazole.
PBMCs are widely used in various research applications, including immunology, cell therapy, vaccine development, and drug discovery. They provide valuable insights into immune responses, allow researchers to study various immune cell populations, and serve as a source of cells for cell-based therapies. PBMCs can be isolated from peripheral blood using techniques such as density gradient centrifugation or specialized cell separation methods.
Additionally, the rise in number of cell therapies, expansion in research & development schemes, increasing focus of key players on R&D in peripheral blood mononuclear cells, increasing focus on regenerative medicine, as well as an increase in demand for cell operations among the population, increasing investigation of various aspects of immunology, infectious diseases, autoimmune disorders, transplantation, and vaccine development are projected to provide market players with lucrative prospects in the future.
Advancements in Toxicology Research
The growth of the peripheral blood mononuclear cells (PBMC) industry is fueled by increasing customer awareness and a rising preference for antibody development. PBMCs play a vital role in biology, pathology, clinical research, and the study of diseases, immunology, and vaccine development. Notably, clinical trials involving PBMCs have surpassed 972 studies, underscoring their significance.
PBMCs provide valuable insights into the effects of potential medication on individuals, particularly their immune systems. Toxicity affecting PBMCs can lead to severe, even fatal, side effects, including immune system suppression and poisoning. Toxicology research is dedicated to evaluating the adverse effects of chemicals, drugs, and environmental factors on living organisms.
In immunotoxicity studies, PBMCs are pivotal for assessing the impact of substances on the immune system. Researchers expose PBMCs to various compounds, analyzing immune responses and identifying immunotoxic effects, including changes in immune cell populations, cytokine production, and immune function. As demand for PBMCs in immunotoxicity research grows, the global peripheral blood mononuclear cells market continues to expand.
Rising Significance of PBMCs in Cell Therapy
Peripheral blood mononuclear cells (PBMCs) are gaining prominence in cell and gene therapy, offering an alternative to traditional regenerative medicines with fewer side effects. In regions like North America and Europe, PBMCs are integral to cell therapies for human well-being.
Awareness is growing about the utility of PBMCs in various treatments, including acute myocardial infarction, chronic heart failure, spinal cord injury, stroke, and wound healing. Successful pre-clinical studies using apoptotic PBMCs' secretome indicate significant market growth potential.
For example, the Centers for Disease Control and Prevention reports approximately 37,300 new cases of HPV+ tumors annually in the U.S., making up 3% of women's malignancies and 2% of men's cancers. With increasing HPV prevalence, companies are focusing on therapy and drug development for the U.S. market, with PBMCs serving as a valuable source of immune cells for cell therapy.
PBMCs encompass various immune cells, including T cells, B cells, and natural killer (NK) cells, all critical for immune responses and disease targeting. These cells provide a versatile resource for different cell therapy approaches.
Adoptive Cell Transfer (ACT), a cell therapy involving immune cell transfer to target diseases like cancer, often starts with PBMCs for isolating and expanding specific T cell subsets. These cells are essential for ACT therapies, supporting market growth.
Increased Investment in R&D for Human Well-Being
The market's growth is driven by rapid advancements in research and development (R&D), leading to novel cell/gene therapies, medications, and products for treating fatal diseases.
PBMCs offer a practical means of obtaining immune proteins from routinely collected blood samples, addressing the analytical challenges posed by highly abundant proteins in native human plasma. Governments worldwide are providing funding for ongoing PBMC research to boost healthcare sector growth.
Moreover, growing awareness of PBMCs' potential in disease research has spurred increased R&D activities, boosting the PBMCs market. PBMCs play a crucial role in early-stage research, assessing the efficacy and safety of potential drug candidates.
As a human-relevant model for studying immune responses and the effects of new compounds on immune cells, PBMCs are increasingly valued in drug discovery. This awareness has fueled demand, driving market growth.
The therapeutic potential of cell-based therapies has been rapidly recognized, with PBMCs playing a pivotal role in their development and manufacturing. Collaborative efforts between academic institutions, research organizations, and the biopharmaceutical industry have contributed to knowledge exchange, joint research projects, and funding initiatives centered on PBMC application in various research areas. This growing awareness and collaborative R&D efforts positively impact the global peripheral blood mononuclear cells market's growth.
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in global peripheral blood mononuclear cells market.
Charles River Laboratories International, Inc.
Lonza Group AG
Corning Inc
Bio-Rad Laboratories Inc
ABCAM
Biolegend Inc
ZEN-Bio Inc
DAPCEL, Inc.
Creative Bioarray
iXCells Biotechnologies USA, LLC
Miltenyi Biotec B.V. & CO. KG
STEMCELL Technologies Inc.
Precision Medicine Group, LLC.
StemExpress, LLC
RayBiotech Life, Inc.
REPROCELL Inc.
Cytologics LLC
BioIVT LLC
Biopredic International
Cell Applications, Inc.
Report Scope:
Voice of Customer
By Type of Product
By Type of Technique
Type of Application for Which PBMCs Are Used
Factors Driving Market Growth
Clinical Trial Analysis
Ongoing Clinical Trials
Completed Clinical Trials
Terminated Clinical Trials
Breakdown of Pipeline, By Development Phase
Breakdown of Pipeline, By Status
Breakdown of Pipeline, By Study Type
Breakdown of Pipeline, By Region
Clinical Trials Heat Map
Peripheral Blood Mononuclear Cells Market, By Product:
Cryopreserved or Frozen PBMC
Cultured or Fresh PBMC
Others
Peripheral Blood Mononuclear Cells Market, By Application:
Immunology
Hematology
Infectious Disease
Others
Peripheral Blood Mononuclear Cells Market, By Techniques:
Density Gradient Centrifugation
Leukapheresis
Others
Peripheral Blood Mononuclear Cells Market, By Source:
Human
Animal
Peripheral Blood Mononuclear Cells Market, By Region:
North America
United States
Canada
Mexico
Europe
Germany
France
United Kingdom
Italy
Spain
Asia-Pacific
China
Japan
India
South Korea
Australia
Singapore
South America
Brazil
Argentina
Colombia
Middle East & Africa
UAE
Saudi Arabia
South Africa
For more information about this report visit https://www.researchandmarkets.com/r/luh8hf
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/global-peripheral-blood-mononuclear-cells-research-report-2023-rd-revolution----pbmcs-paving-the-way-for-medical-breakthroughs-301947470.html
SOURCE Research and Markets
